Navigation Links
Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper
Date:4/14/2011

efore the start of the call to register and identify themselves as registrants of the 'Adeona' Conference Call. Any registered caller on the toll free line may ask to be placed in the queue for the Question & Answer session. The call will be simulcast on the web at http://www.videonewswire.com/event.asp?id=78671. If you are unable to participate during the live call, the webcast will be available for replay at www.adeonapharma.com for 30 days after the call.

About reaZin Clinical Study

Two scientific observations support Adeona's hypothesis that correcting zinc and free copper abnormalities could benefit AD patients as measured by cognitive scores. The first observation is derived from studies conducted by Dr. Squitti and her group that have shown the following: 1) AD patients have elevated levels of serum free copper(2) and 2) the elevated levels of free copper correlate with lower cognitive function(3) and, over time, a decline in cognitive function(4). The second observation is the finding that AD patients are zinc deficient compared to age-matched control patients(5). These findings suggest that elevated free copper is toxic to the brain of AD patients. Therefore, based on these scientific observations, Adeona's therapeutic strategy for the reaZin clinical study is to correct zinc deficiency and to lower serum free copper in AD patients. Based on findings in Wilson's disease (a disease characterized by toxic levels of free copper), oral zinc is known to lower serum free copper.

The prospective, randomized, double-blind, placebo-controlled clinical study represents the first controlled clinical study evaluating the safety and efficacy of a zinc and cysteine-based therapy (reaZin) for Alzheimer's disease. Study subjects were randomized into the active treatment group or the placebo group and wer
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial
2. New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions
3. GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome
4. Visual Healthcare to Support Chinese Clinical Trials
5. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
6. Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant
7. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
8. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
9. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
10. Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance
11. Boston Scientific Begins International Clinical Trial Enrollment for INNOVA™ Self-Expanding Bare-Metal Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... BETHESDA, Md. , June 19, 2013 /PRNewswire/ -- ... "Company"), an American healthcare company providing services in ... of United Family Healthcare, a network of private ... official opening of its Beijing United Family Rehabilitation ... development projects of the United Family Healthcare ("UFH") ...
(Date:6/19/2013)... N.Y. , June 19, 2013 ... sourcing company servicing all branches of government from ... they have expanded their facilities to include complex ... designed and fabricated some very complex aluminum parts ... continue to expand our capabilities to service government ...
(Date:6/19/2013)... June 19, 2013 DST Health Solutions, LLC ... to health plans, integrated delivery systems, and health care ... Drug Management Service (MDMS) has jumped significantly. ... automate the pricing of medical prescription drug claims, MDMS ... automating their medical drug claims processes. As specialty drug ...
Breaking Medicine Technology:Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5Amerivet Solutions Expands to Manufacture Complex Metal Designs 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3
... 27 ChemoCentryx, Inc., today announced that ... PROTECT-1 Study (the Prospective Randomized Oral Therapy ... (CCX282-B) in patients with moderate-to-severe Crohn,s disease. ... antagonist showed clinical efficacy in a 12-week ...
... NANJING, China, Oct. 27 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... specializing in the development, manufacturing, and marketing of branded ... it will report its unaudited financial results for the ... 11, 2010, before the market opens in the United ...
Cached Medicine Technology:ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 2ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 3ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 4ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 5Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010 2
(Date:6/19/2013)... Arbor, Mich. Children had half as many ... evening office hours on five or more days a ... at C.S. Mott Children,s Hospital and Johns Hopkins University. ... in The Journal of Pediatrics and will ... "These findings are an important step in understanding where ...
(Date:6/19/2013)... ROCHESTER, Minn. -- Nearly 70 percent of ... and more than half take two, Mayo Clinic ... most commonly prescribed, their study found. Twenty percent ... medications, according to the findings, published online in ... MULTIMEDIA ALERT: For audio and video of Dr. ...
(Date:6/19/2013)... June 19, 2013 North Carolina-based ... organizational changes to advance development of its technologies. ... “To support the advanced development of our product ... to the Company’s management structure and engaged industry ... Company announced that Michael Galiger will serve as ...
(Date:6/19/2013)... Brightree LLC , the leading provider of ... post-acute care industry, has been ranked for the first time ... 100 (HCI 100) list. This prestigious list features the ... of revenue during the last fiscal year. Since 2005, Brightree’s ... and the company has built its organization to more than ...
(Date:6/19/2013)... Many trying-to-conceive couples seek medical ... according to a recent study published ... results of this research confirm what Fairhaven Health ... – that trying-to-conceive women would benefit from tracking ... weight. Fairhaven Health is a leading provider of ...
Breaking Medicine News(10 mins):Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4
... More than 90% of drugs entering,clinical development fail ... of,effectiveness or adverse side effects not detected in ... pre-clinical tests using stem cell,technologies, potentially saving drug ... Cells: Worldwide Markets for,Transplantation, Cord Blood Banking and ...
... condition associated with pregnancy responds to energy restoration, ... the editor,in today,s USA Today, board-certified cardiologist Stephen T. ... a rare and often,misunderstood form of heart disease. Responding ... twins who developed peripartum cardiomyopathy, an,uncommon and mystifying type ...
... Transcept,Pharmaceuticals, Inc. today announced that Glenn A. ... the BioCentury "Future,Leaders in the Biotech Industry" Conference ... New York City on Thursday, March 27, 2008 ... Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical ...
... GlaxoSmithKline (NYSE: GSK ),today reported its ... equivalent to almost 4% of pre-tax profits for ... Donations of albendazole treatments,for the company,s flagship program ... valued at $29 million, bringing the,total number of ...
... of natural compound found in heparin samples , , WEDNESDAY, ... they,ve identified the contaminant found in the blood-thinner heparin, ... and possibly 19 deaths in the United States. , ... sulfate, but U.S. Food and Drug Administration officials could ...
... Profits before ... Patients, ST. ... their side, International Union of Operating,Engineers Local 49 leaders today at a ... off medical coverage to,several thousand Minnesota seniors., "This is a death ...
Cached Medicine News:Health News:Stem Cell Technology Offers Promise of Huge Savings for Drug Developers 2Health News:Metabolic Cardiologist Offers New Hope for Women With Heart Disease 2Health News:GSK Charitable Support Valued at $564 Million in 2007 2Health News:GSK Charitable Support Valued at $564 Million in 2007 3Health News:FDA Identifies Contaminant in Blood-Thinning Drug 2Health News:FDA Identifies Contaminant in Blood-Thinning Drug 3Health News:Park Nicollet to Cut Off Care to Thousands of Minnesota Seniors 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: